Kevin Dennis Green Sells 23,147 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 23,147 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total transaction of $33,563.15. Following the completion of the sale, the chief financial officer now owns 912,607 shares in the company, valued at approximately $1,323,280.15. This trade represents a 2.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 7th, Kevin Dennis Green sold 31,148 shares of Cerus stock. The stock was sold at an average price of $1.50, for a total transaction of $46,722.00.
• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Stock Down 1.4 %

Cerus stock opened at $1.43 on Wednesday. The company has a market cap of $265.68 million, a P/E ratio of -13.00 and a beta of 1.56. Cerus Co. has a 1-year low of $1.38 and a 1-year high of $2.54. The company has a fifty day simple moving average of $1.72 and a 200 day simple moving average of $1.75. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The business had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. Research analysts anticipate that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 price objective on shares of Cerus in a research report on Friday, February 21st.

Institutional Trading of Cerus

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Cerus by 1.6% in the third quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock valued at $7,685,000 after acquiring an additional 69,950 shares during the last quarter. State Street Corp lifted its stake in Cerus by 2.2% in the third quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock valued at $6,506,000 after acquiring an additional 79,505 shares during the last quarter. Barclays PLC lifted its stake in Cerus by 16.2% in the third quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock valued at $2,740,000 after acquiring an additional 219,755 shares during the last quarter. Stifel Financial Corp lifted its stake in Cerus by 12.0% in the third quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock valued at $461,000 after acquiring an additional 28,383 shares during the last quarter. Finally, ARK Investment Management LLC lifted its stake in shares of Cerus by 14.2% during the 4th quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company’s stock worth $32,055,000 after buying an additional 2,589,721 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.